Document bawmq6n7gqw2rYq02e4dkDm7Z

Larry K. Zobel, MD, M W *Staff Vice President and Medic*] Director 3M Medical Department 3M Center, Building Q220-02-E-02 FO Box 33220 S t Rani, MN 55133-3220 651 733 3181 Office 651 733 5152 Hue March 19,2002 Document Processing Center (7407) ATTN: Section 8(e) Coordinator Office o f Pollution, Prevention and Toxics US Environmental Protection Agency 401 M Street, SW Washington, D.C. 20460 Re: TSCA 8(e) Supplemental Notice for Sulfonate-based and Carboxylic-based Fluorochemicals - Docket Numbers 8EHQ-1180-373; 8EHQ-1180-374; 8EHQ-03810394; 8EHQ-0S98-373 Dear Docket Coordinator: With this letter, 3M is providing final reports and other supplemental information related to previous TSCA Section 8(e) notifications. All o f the enclosed items are already in EPA's possession and available in TSCA Docket AR-226. We believe, however, that placing these items in the 8(e) docket may allow for more convenient access to information directly related to previous 8(e) notifications by 3M. The reports enclosed are as follows: 1. Final Report, Identification o f Fluorochemicals in Human Sera. I. American Red Cross Adult Blood Donors, February 2S, 2002. 2. Final Report, Identification o f Fluorochemicals in Human Sera. II. Elderly Participants o f the Adult Changes in Thought Study, Seattle, Washington, February 25,2002. 3. Final Report, Identification o f Fluorochemicals in Human Sera. III. Pediatric Participants in a Group A Streptococci Clinical Trial Investigation, March 15. 2002. 4. Interim Report #2. Determination of Serum Half-Lives o f Several Fluorochemicals, January 11.2002. March 19,2002 Page 2 5. Final Report, A Longitudinal Analysis o f Serum Perfluorooctanesulfonate (PFOS) and Perfluorooctanoate (PFOA) in Relation to Clinical Chemistry, Thyroid Hormone, Hematology and Urinalysis Results from Male and Female Employee Participants o f the 2000 Antwerp and Decatur Fluorochemical Medical Surveillance Program, October 11,2001. 6. Final Report, A Longitudinal Analysis o f Serum Perfluorooctanesulfonate (PFOS) and Perfluorooctanoate (PFOA) Levels in Relation to Lipid and Hepatic Clinical Chemistry Test Results from Male Employee Participants o f the 1994/95,1997 and 2000 Fluorochemical Medical Surveillance Program, October 11,2001. In addition, 3M contracted with Dr. David Gaylor o f Sciences International, Inc. to calculate benchmark doses for low-dose cancer risk assessment based on the results from the cancer bioassays in rats with N-EtFOSE and PFOS. These two-year bioassay reports were submitted on February 8,2002. Dr.Gaylor's reports provide values for the lower 95th percent confidence limit o f the benchmark dose (BMDLio) in terms of dietary concentration o f N-EtFOSE or PFOS, respective to the test compound used in the study, and serum PFOS concentration, as measured at 14-weeks o f dosing. 7. Benchmark Doses for Tumor in Sprague Dawley Rats fed N-Ethyl Perfluarooctanesulfonamido Ethanol (N-EtFOSE), January 31,2002. 8. Benchmark Doses for Liver Tumors in Sprague Dawley Rats fed Perfluorooctane Sulfonic Acid Potassium Salt (PFOS), January 24,2002. Please contact Dr. John Butenhoff., 651-733-1962, or Dr. Geary Olsen, 651-737-8569, for further information on these studies. Regards, Larry R. Zobel, MD MPH Staff Vice President & Medical Director cc: J.L. Butenhoff- 220-2E-02 G.W. Olsen-220-3W -05